10-Q: Varex Imaging Reports Mixed Q2 Results Amidst Economic Headwinds

Varex Imaging Corporation's second quarter results show a decrease in revenue and profit compared to the previous year, impacted by economic uncertainty and supply chain challenges.

Summary

• Varex Imaging Corporation reported a net revenue of $206.2 million for the three months ended March 29, 2024, a decrease from $228.2 million in the same period last year.
• Gross profit also declined to $65.8 million from $72.7 million year-over-year.
• Net income attributable to Varex was $1.4 million, down from $4.1 million in the prior year's quarter.
• For the six months ended March 29, 2024, net revenue was $396.2 million, compared to $433.8 million in the same period last year.
• Net income attributable to Varex for the six-month period was $0.9 million, a significant decrease from $7.2 million in the prior year.
• The company experienced fewer supply chain issues in fiscal year 2024 compared to 2023, but still faces challenges with certain materials and delivery delays.
• The Medical business was negatively impacted by the China government's anti-corruption campaign and cautious customer purchasing behavior.
• The company's backlog was approximately $330 million as of March 29, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant challenges in revenue and profit, but also some positive developments in supply chain and strategic moves. The overall tone is cautious, reflecting the uncertain economic environment and the company's need to navigate various risks.

Positives

• The company experienced fewer supply chain, manufacturing, and logistics challenges in fiscal year 2024 compared to fiscal year 2023.
• The Industrial segment saw a revenue increase of $3.3 million.
• Varex secured a new $155 million senior secured revolving credit facility.
• The company increased its ownership in MeVis Breastcare, resulting in a gain on bargain purchase of $1.2 million.

Negatives

• The Medical segment experienced a significant revenue decrease of $25.3 million.
• Net income attributable to Varex decreased significantly in both the three and six-month periods.
• The company's business in China has been negatively impacted by the government's anti-corruption campaign.
• The company faces cautious purchasing behaviors by customers.
• Gross profit decreased due to decreased sales volume and an unfavorable shift in product sales mix.
• Selling, general, and administrative expenses increased due to increased fixed cost commitments and litigation costs.

Risks

• The company is exposed to risks related to economic instability, supply chain disruptions, and geopolitical tensions.
• The company relies on a limited number of OEM customers, and a loss of business from one or more of these customers could materially reduce sales.
• The company faces intense competition and pricing pressures in its markets.
• The company's success depends on the successful development and commercialization of new products and enhancements to existing product lines.
• The company is subject to risks associated with international manufacturing, operations, and sales.
• The company may be unable to complete future acquisitions or realize expected benefits from acquisitions.
• The company is subject to potential product liability claims and may be required to recall products.
• The company is exposed to risks related to intellectual property rights and information systems.
• The company is subject to various legal and regulatory requirements, including compliance with FDA regulations and international laws.
• The company is subject to risks related to its indebtedness, including limitations imposed by debt financing agreements.
• The company's Convertible Notes mature in June 2025, and failure to refinance them could result in a material adverse effect on the company's results of operations and financial position.

Future Outlook

The company expects the negative trends in its Medical business due to the China government's anti-corruption campaign and cautious customer purchasing behavior to continue through the remainder of fiscal year 2024. The company anticipates refinancing its Convertible Notes due in June 2025 using a combination of future borrowings under its Revolving Credit Facility and cash.

Management Comments

• The company remains cautious about the general economic environment as many factors remain dynamic and unpredictable.
• The company continues to work to improve the life and quality of its imaging components and leverage its scale as one of the largest independent X-ray imaging component suppliers to provide cost-effective solutions for its customers.
• The company is developing CT X-ray tubes and related subsystems for Chinese OEMs as they introduce new systems in China.
• The company continues to expand manufacturing capabilities at its facilities in China, Germany, the Netherlands, and the Philippines to mitigate the impact of tariffs and be closer to its global customer base.

Industry Context

The announcement reflects the challenges faced by medical device companies in the current economic climate, including supply chain disruptions, inflation, and geopolitical tensions. The impact of the Chinese government's anti-corruption campaign on the healthcare industry is also a significant factor affecting Varex's performance.

Comparison to Industry Standards

• Compared to other medical imaging component manufacturers, Varex's revenue decline reflects broader industry trends of reduced capital spending and supply chain issues.
• Competitors like Canon Medical Systems, who are also customers, may be experiencing similar challenges, but their in-house manufacturing capabilities could provide a buffer.
• The company's focus on expanding manufacturing capabilities in multiple regions aligns with industry trends of diversifying supply chains to mitigate risks.
• The company's investment in R&D, while currently a higher percentage of revenue, is consistent with the need for innovation in the medical imaging sector, similar to companies like Siemens Healthineers and Philips Healthcare.
• The company's debt levels and refinancing plans are comparable to other companies in the sector that have taken on debt for acquisitions and expansion.

Legal Proceedings

• The company is a party to certain products liability litigation which, if adversely determined, could have an adverse material impact on its financial results.
• The partners to the VEC joint venture filed judicial proceedings in Germany against one another disputing the validity of shareholder resolutions passed in January 2023.
• In February 2024, Varex Imaging Deutschland AG filed another lawsuit to enforce its version of similar shareholder resolutions passed in January 2024.

Related Party Transactions

• The company has a 40% ownership interest in dpiX Holding LLC, a supplier of amorphous silicon-based thin film transistor arrays.
• The company has a 50% interest in VEC Imaging GmbH & Co. KG, a joint venture formed to develop technology for use in X-ray imaging components.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and profit.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may experience delays in product delivery due to supply chain issues.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's ability to meet its debt obligations.

Next Steps

• The company will continue to monitor the economic environment and supply chain challenges.
• The company will focus on improving the life and quality of its imaging components and leverage its scale.
• The company will continue to expand manufacturing capabilities at its facilities in China, Germany, the Netherlands, and the Philippines.
• The company will work to mitigate the impact of tariffs and be closer to its global customer base.
• The company will refinance its Convertible Notes due in June 2025 using a combination of future borrowings under its Revolving Credit Facility and cash.

Key Dates

Keywords

X-ray imaging, medical devices, industrial inspection, digital detectors, X-ray tubes, supply chain, financial results, revenue, profit, debt, capital, China, healthcare, security, manufacturing